Krazati
Payments companies reported to CMS as associated with Krazati. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Krazati, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Krazati
These are the largest totals companies reported as associated with Krazati. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $152,626.49 |
| Eric Nadler | Dallas, TX | Medical Oncology | $104,583.99 |
| Hatim Husain | San Diego, CA | Internal Medicine | $74,591.40 |
| Ani Balmanoukian | Baltimore, MD | Hematology & Oncology | $54,593.92 |
| Edgardo Santos | Fort Lauderdale, FL | Hematology & Oncology | $42,984.02 |
| Jewel Johl | Walnut Creek, CA | Hematology & Oncology | $41,998.91 |
| Pamela Calarese | Boston, MA | Acute Care (Nurse Practitioner) | $39,037.57 |
| Mohamed Mohamed | Greensboro, NC | Hematology (Internal Medicine) | $38,838.17 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $38,377.54 |
| Michelle Turner | Baltimore, MD | Nurse Practitioner | $37,939.76 |
Prescribed Krazati?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.